Coeliac Plexus Visceral Fat: Evidence and UK Care

Coeliac plexus visceral fat research sits at the intersection of autonomic neuroscience and metabolic medicine, raising important questions about how abdominal nerve networks influence fat distribution and metabolic health. The coeliac plexus, a major sympathetic nerve hub in the upper abdomen, has been proposed as a potential regulator of visceral adipose tissue, the metabolically active fat stored around abdominal organs. While preclinical studies have generated interest in this area, human evidence remains limited. This article explains what the coeliac plexus is, how it may relate to visceral fat and metabolic conditions, what interventions are being investigated, and what current UK clinical guidance says.

What is the coeliac plexus and how does it affect body fat?

The coeliac plexus is a sympathetic nerve network in the upper abdomen that may influence visceral fat via autonomic signalling, but causal relationships in humans remain unconfirmed and current evidence is largely preclinical.

The coeliac plexus is a dense network of sympathetic nerve ganglia located in the upper abdomen, surrounding the coeliac artery, and it plays a central role in regulating autonomic signals to abdominal organs including the liver, pancreas, stomach and intestines.^[24] Sometimes called the solar plexus, it acts as a relay station for sympathetic and parasympathetic nerve fibres that govern digestive function, hormonal secretion and, increasingly, metabolic processes linked to fat distribution.

Visceral fat, the adipose tissue stored around abdominal organs rather than beneath the skin, is metabolically active and influenced by the autonomic nervous system. Sympathetic nerve activity stimulates lipolysis (the breakdown of stored fat) by activating beta-adrenergic receptors on adipocytes. The relationship between sympathetic tone and visceral fat accumulation is complex: obesity is frequently associated with sympathetic overactivity rather than reduced activity, and the precise mechanisms by which autonomic signalling shapes fat distribution in humans remain an active area of investigation.^[15][16] Mechanistic claims in this field should be understood as associative or hypothesis-generating rather than established causal relationships.

Some research, largely from animal and preclinical studies, suggests that visceral adipose tissue may be more densely innervated by sympathetic nerves than subcutaneous fat, which could make it particularly responsive to autonomic signalling.^[13][14] Whether this translates meaningfully to human physiology is not yet confirmed. The coeliac plexus, as a major hub of abdominal sympathetic outflow, has been proposed as a potential anatomical target for understanding visceral fat distribution, but this remains a hypothesis with limited human data to support it. Clinical applications in this area are largely experimental at this stage.

Can coeliac plexus nerve activity be linked to metabolic conditions?

Dysregulated coeliac plexus activity has been associated with type 2 diabetes, MASLD and insulin resistance, but these links are observational and no UK guideline recommends coeliac plexus assessment in routine metabolic evaluation.

Dysregulated coeliac plexus nerve activity has been associated with several metabolic conditions, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD, previously termed non-alcoholic fatty liver disease or NAFLD) and obesity-related insulin resistance, though the precise causal relationships are still being established. The autonomic nervous system exerts significant influence over insulin secretion from the pancreas, hepatic glucose output and adipokine release from visceral fat depots, all of which are modulated by signals passing through or near the coeliac plexus. These associations are based on observational and preclinical data and should not be interpreted as confirmed causal mechanisms.

In individuals with obesity, sympathetic nervous system overactivity is a well-recognised phenomenon. The relationship between sympathetic tone and visceral fat is bidirectional and complex, involving feedback loops with cortisol, catecholamines and inflammatory cytokines. The coeliac plexus sits at the intersection of these pathways, receiving and transmitting signals that influence both energy storage and expenditure. Animal studies have demonstrated that selective denervation of visceral adipose tissue can alter insulin sensitivity and fat distribution in experimental models, raising the possibility that targeted neural modulation could have metabolic effects, though these findings have not been replicated in robust human trials.^[13]

Chronic pain conditions affecting the upper abdomen, such as those arising from pancreatic disease, can also disrupt normal coeliac plexus signalling. Patients with chronic pancreatitis frequently experience significant weight loss and nutritional deficiency; the primary drivers are exocrine insufficiency, reduced dietary intake and pain-related anorexia, with any contribution from altered autonomic signalling being less well established.^[7][19] Understanding these connections may help clinicians better interpret metabolic changes in patients with abdominal pathology. No UK clinical guideline, including those from NICE, currently recommends coeliac plexus assessment as part of routine metabolic evaluation.^[2][3]

What treatments target coeliac plexus pathways for fat-related disorders?

No coeliac plexus treatment is licensed in the UK for visceral fat or obesity; NICE-endorsed options include lifestyle intervention, orlistat, semaglutide and tirzepatide, subject to eligibility and ICB commissioning.

Currently, no treatment specifically targeting the coeliac plexus is licensed in the UK for the management of visceral fat or obesity, and any interventions in this area remain investigational. The most established coeliac plexus procedure in UK clinical practice is coeliac plexus block or neurolysis, which is used primarily for pain management in conditions such as pancreatic cancer or chronic pancreatitis, rather than for metabolic or weight-related indications.^[1][20]

In the research setting, renal denervation, a related concept targeting sympathetic nerves around the renal arteries, has been studied for resistant hypertension and has prompted interest in whether similar approaches targeting abdominal sympathetic ganglia could influence metabolic outcomes.^[11][12] Splanchnic nerve ablation, which targets nerves feeding into the coeliac plexus, is being investigated in early-phase trials for heart failure and obesity-related conditions.^[9][10] Some preliminary data have suggested possible effects on metabolic markers, but these studies are at an early stage and have not yet produced evidence sufficient to support routine clinical use.

For individuals seeking evidence-based treatment for obesity and its metabolic consequences, options recommended by NICE include structured lifestyle interventions, pharmacotherapy and, for eligible patients, bariatric surgery. Pharmacotherapy options endorsed through NICE technology appraisals include orlistat, GLP-1 receptor agonists such as semaglutide, and the dual GIP and GLP-1 receptor agonist tirzepatide (Mounjaro), which is authorised by the MHRA for both type 2 diabetes and chronic weight management.^[2][3] Access to these treatments through the NHS depends on Integrated Care Board (ICB) commissioning and local specialist pathways, and eligibility criteria apply. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations with prescriber review and pharmacist support; tirzepatide is one option a prescriber may consider after assessment and only where it is clinically appropriate.

Are there risks or side effects associated with coeliac plexus interventions?

Common side effects include transient hypotension and diarrhoea; serious but rare complications include retroperitoneal haematoma, neurological injury and paraplegia, and procedures are only performed in specialist settings.

Coeliac plexus block and neurolysis carry recognised procedural risks that clinicians and patients should discuss thoroughly before proceeding, and these procedures are only performed in specialist settings under imaging guidance. They are not appropriate for everyone: key contraindications and precautions include coagulopathy or current anticoagulant or antiplatelet therapy (which increases bleeding risk), active local or systemic infection, and distorted upper abdominal anatomy that may complicate safe needle placement. Pre-procedure assessment should address these factors, and anticoagulation management should be planned in advance with the specialist team.

The most commonly reported adverse effects include transient hypotension (low blood pressure), diarrhoea and local pain at the injection site, which typically resolve within a few days.^[8] These effects arise because disrupting sympathetic outflow to the gut alters vascular tone and bowel motility.

More serious but less frequent complications include retroperitoneal haematoma, infection, pneumothorax and, in rare cases, neurological injury such as paraplegia, which can occur if the needle inadvertently damages spinal vessels or the spinal cord.^[8][20] The risk profile differs depending on whether the procedure is performed percutaneously (through the skin), endoscopically (via endoscopic ultrasound guidance) or surgically. Endoscopic ultrasound-guided approaches are increasingly used in UK specialist centres, though comparative complication data vary by indication and operator experience.

For any experimental or investigational procedure targeting the coeliac plexus for metabolic purposes, patients should be aware that the long-term safety profile is not yet established. Participants in clinical trials should report any adverse events to the trial team under the study protocol. Suspected side effects from licensed medicines used alongside such procedures can be reported to the MHRA via the Yellow Card scheme (available at yellowcard.mhra.gov.uk). Anyone experiencing severe abdominal pain, sudden onset of weakness in the legs, or signs of infection following a coeliac plexus procedure should attend an accident and emergency department immediately. For non-urgent concerns following a procedure, contacting the specialist team who performed the procedure or a GP is the appropriate first step.

What does current UK clinical evidence say about this area of research?

UK clinical evidence is limited to preclinical and early-phase studies; no NICE guideline endorses coeliac plexus interventions for obesity, and evidence-based care should follow current NICE guidance on visceral adiposity.

UK clinical evidence specifically linking coeliac plexus interventions to visceral fat reduction is limited, and no NICE guideline or NHS commissioning policy currently endorses coeliac plexus targeting as a strategy for managing obesity or metabolic disease. The evidence base is largely derived from preclinical studies, small observational series and early-phase trials, most of which have been conducted outside the UK. Translating these findings into robust clinical recommendations requires larger, well-designed randomised controlled trials with long-term follow-up.

Research groups in the UK are contributing to the broader field of autonomic modulation for metabolic disease, including work on vagal nerve stimulation and renal denervation, which share conceptual overlap with coeliac plexus approaches. To the best of available information, the British Society of Gastroenterology and the British Pain Society have not issued position statements on coeliac plexus interventions for metabolic indications, which reflects the early stage of the evidence in this area.

For patients and clinicians interested in this area, it is important to distinguish between established pain management uses of coeliac plexus procedures, which are supported by clinical evidence and available through NHS specialist services, and experimental metabolic applications, which remain confined to research settings. Patients who are interested in participating in relevant clinical trials can search the NIHR Clinical Research Network portfolio, the ISRCTN registry or ClinicalTrials.gov for registered studies. In the meantime, evidence-based management of visceral adiposity and associated metabolic conditions should follow current NICE guidance, which prioritises lifestyle modification, pharmacotherapy and, where appropriate, surgical intervention for eligible individuals, with access subject to ICB commissioning and local specialist pathways.

Frequently Asked Questions